Literature DB >> 27939437

The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.

Zhiyong Liu1, Andrew B West2.   

Abstract

The evolutionarily conserved enzyme encoded by the leucine-rich repeat kinase 2 gene, LRRK2, harbors both a Rab-like GTPase domain and a serine/threonine protein kinase domain. Pathogenic mutations in either the GTPase or kinase domain can cause neurodegeneration and Parkinson disease. No high-resolution structure of the human LRRK2 kinase domain is available but the most common mutation, G2019S in the kinase domain, is predicted to alter the ATP-binding pocket structure and interaction with divalent cations. Here we find that the manganese-bound kinase domain acquires a robust ability to utilize both GTP as well as ATP in autophosphorylation of the GTPase domain and phosphorylation of peptide substrates in vitro. The G2019S LRRK2 mutation increases the efficiency of GTP-mediated kinase activity ten-fold compared to WT LRRK2 activity. Moreover, GTP-dependent phosphorylation alters autophosphorylation-site preference in vitro. While additional studies are required to determine the physiological relevance of these observations, LRRK2 is one of the only known kinases to be able to utilize GTP as a phospho-donor at physiological levels in vitro, and thus one of the only known proteins to be able to hydrolyze GTP in two distinct domains within the same protein.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dardarin; Enzyme kinetics; Manganese; Nucleotide-binding pocket; PARK8; ROCO4

Mesh:

Substances:

Year:  2016        PMID: 27939437      PMCID: PMC5278637          DOI: 10.1016/j.bbapap.2016.12.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta Proteins Proteom        ISSN: 1570-9639            Impact factor:   3.036


  37 in total

1.  GTP plus water mimic ATP in the active site of protein kinase CK2.

Authors:  K Niefind; M Pütter; B Guerra; O G Issinger; D Schomburg
Journal:  Nat Struct Biol       Date:  1999-12

2.  Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.

Authors:  Giambattista Guaitoli; Francesco Raimondi; Bernd K Gilsbach; Yacob Gómez-Llorente; Egon Deyaert; Fabiana Renzi; Xianting Li; Adam Schaffner; Pravin Kumar Ankush Jagtap; Karsten Boldt; Felix von Zweydorf; Katja Gotthardt; Donald D Lorimer; Zhenyu Yue; Alex Burgin; Nebojsa Janjic; Michael Sattler; Wim Versées; Marius Ueffing; Iban Ubarretxena-Belandia; Arjan Kortholt; Christian Johannes Gloeckner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

3.  Characterization of the Roco protein family in Dictyostelium discoideum.

Authors:  Wouter N van Egmond; Peter J M van Haastert
Journal:  Eukaryot Cell       Date:  2010-03-26

4.  The role of the metal ion in the p21ras catalysed GTP-hydrolysis: Mn2+ versus Mg2+.

Authors:  T Schweins; K Scheffzek; R Assheuer; A Wittinghofer
Journal:  J Mol Biol       Date:  1997-03-07       Impact factor: 5.469

5.  Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.

Authors:  Jaclyn L Henderson; Bethany L Kormos; Matthew M Hayward; Karen J Coffman; Jayasankar Jasti; Ravi G Kurumbail; Travis T Wager; Patrick R Verhoest; G Stephen Noell; Yi Chen; Elie Needle; Zdenek Berger; Stefanus J Steyn; Christopher Houle; Warren D Hirst; Paul Galatsis
Journal:  J Med Chem       Date:  2014-11-17       Impact factor: 7.446

6.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.

Authors:  Junpeng Deng; Patrick A Lewis; Elisa Greggio; Eli Sluch; Alexandra Beilina; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

7.  Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.

Authors:  Anthony A Estrada; Xingrong Liu; Charles Baker-Glenn; Alan Beresford; Daniel J Burdick; Mark Chambers; Bryan K Chan; Huifen Chen; Xiao Ding; Antonio G DiPasquale; Sara L Dominguez; Jennafer Dotson; Jason Drummond; Michael Flagella; Sean Flynn; Reina Fuji; Andrew Gill; Janet Gunzner-Toste; Seth F Harris; Timothy P Heffron; Tracy Kleinheinz; Donna W Lee; Claire E Le Pichon; Joseph P Lyssikatos; Andrew D Medhurst; John G Moffat; Susmith Mukund; Kevin Nash; Kimberly Scearce-Levie; Zejuan Sheng; Daniel G Shore; Thuy Tran; Naimisha Trivedi; Shumei Wang; Shuo Zhang; Xiaolin Zhang; Guiling Zhao; Haitao Zhu; Zachary K Sweeney
Journal:  J Med Chem       Date:  2012-10-15       Impact factor: 7.446

8.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis.

Authors:  Patrick A Lewis; Elisa Greggio; Alexandra Beilina; Shushant Jain; Acacia Baker; Mark R Cookson
Journal:  Biochem Biophys Res Commun       Date:  2007-04-10       Impact factor: 3.575

9.  Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Authors:  Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2011-03-06       Impact factor: 15.040

Review 10.  Copper and copper proteins in Parkinson's disease.

Authors:  Sergio Montes; Susana Rivera-Mancia; Araceli Diaz-Ruiz; Luis Tristan-Lopez; Camilo Rios
Journal:  Oxid Med Cell Longev       Date:  2014-01-08       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.